COMMUNIQUÉS West-GlobeNewswire

Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines
16/01/2025
$16M extension round led by J2 Ventures and GHIC builds on support from BARDA, CEPI, the Bill & Melinda Gates Foundation and others to simplify access to life-saving drugs ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- [...]
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
16/01/2025
ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks BLA resubmission on track for calendar Q1 2025 Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in [...]
KFSHRC Launches Precision Medicine Services in Family Medicine Clinics to Enhance Access to the Latest Genetic Tests
16/01/2025
RIYADH, Saudi Arabia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has launched precision medicine services within its Family Medicine Clinics, aiming to advance [...]
Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders
16/01/2025
Fabio Dorigotti brings over 25 years of clinical development experience Joins Actimed following retirement of Frank Misselwitz London, UK – 16 January 2025. Actimed Therapeutics, a UK based clinical stage speciality [...]
Phonak expands award-winning Infinio portfolio with two new custom hearing aids
16/01/2025
Phonak, a leading global provider of life-changing hearing solutions, is proud to announce the expansion of its highly acclaimed Infinio technology platform with the introduction of two new in-the-ear (ITE) hearing aids [...]
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
16/01/2025
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute [...]
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
14/01/2025
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ [...]
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue
14/01/2025
Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of approximately 30% compared to the prior-year period. Fourth quarter 2024 recurring revenue expected to be [...]
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
14/01/2025
FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance [...]
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
14/01/2025
Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants [...]
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/01/2025
BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified [...]
Evaxion announces completion of ADS ratio change
14/01/2025
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that [...]
OP Solutions Appoints Michael Kallish as Chief Executive Officer
14/01/2025
Experienced HIT Executive to Lead Next Stage of Growth for Orthotic & Prosthetic EMR Provider Tampa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- OP Solutions , the emerging leader in comprehensive technology solutions for [...]
UPDATE - Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles
14/01/2025
U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines SAN FRANCISCO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
14/01/2025
Déclaration de transactions sur actions propres Paris, France (14 janvier 2025, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2024, EssilorLuxottica déclare que du 7 janvier 2025 [...]
Report on Carbios’ liquidity contract with Natixis ODDO BHF
14/01/2025
Shares concerned: Carbios (ISIN code: FR0011648716) Market concerned: Euronext Growth Paris Clermont-Ferrand (France), 14 January 2025 (6:00 pm CET). CARBIOS , (Euronext Growth Paris: ALCRB), a pioneer in the [...]
CARBIOS : Bilan semestriel du contrat de liquidité confié à Natixis ODDO BHF
14/01/2025
Titre concerné : CARBIOS (code ISIN FR0011648716) Marché concerné : Euronext Growth Paris Clermont-Ferrand (France), le 14 janvier 2025 (18h00 CET). CARBIOS, (Euronext Growth Paris : ALCRB), pionnière dans le [...]
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters’ Over-Allotment Option
14/01/2025
Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2024
14/01/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]

Pages